Association of IL-9 Cytokines with Hepatic Injury in Infection
Overview
Molecular Biology
Authors
Affiliations
Cystic echinococcosis (CE) is a zoonotic disease caused by the parasite (), which can lead to the formation of liver lesions. Research indicates that releases both Toll-like receptor 2 (TLR2) and Interleukin-9 (IL-9), which can potentially impair the body's innate immune defenses and compromise the liver's ability to fight against diseases. To investigate the role of TLR2 and IL-9 in liver damage caused by infection, samples were initially collected from individuals diagnosed with CE. Subsequently, BALB/c mice were infected with at multiple time points (4 weeks, 12 weeks, 32 weeks) and the expression levels of these markers was then assessed at each of these phases. Furthermore, a BALB/c mouse model was generated and administered anti-IL-9 antibody via intraperitoneal injection. The subsequent analysis focused on the TLR2/MyD88/NF-κB signaling pathway and the expression of IL-9 in was examined. A co-culture experiment was conducted using mouse mononuclear macrophage cells (RAW264.7) and hepatic stellate cells (HSCs) in the presence of Protein (EgP). The findings indicated elevated levels of IL-9 and TLR2 in patients with CE, with the activation of the signaling pathway significantly increased as the duration of infection progressed. Administration of anti-IL-9 in mice reduced the activation of the TLR2/MyD88/NF-κB signaling pathway, exacerbating liver injury. Moreover, EgP stimulates the TLR2/MyD88/NF-κB signaling pathway, resulting in the synthesis of α-SMA and Collagen I. The data suggest that infection with may stimulate the production of IL-9 through the activation of the TLR2/MyD88/NF-κB signaling pathway, which is mediated by TLR2. This activation stimulates RAW264.7 and HSCs, exacerbating liver injury and fibrosis.
Zhu J, Zhou T, Chen G, Gao H, Chen X, Tuohetali A Vet Res. 2025; 56(1):55.
PMID: 40065480 PMC: 11895129. DOI: 10.1186/s13567-025-01478-z.
Zhu J, Zhou T, Chen G, Wu Y, Chen X, Song Y Front Immunol. 2025; 15:1512180.
PMID: 39749332 PMC: 11693510. DOI: 10.3389/fimmu.2024.1512180.